98%
921
2 minutes
20
Synchronous multiple endocrine gland metastasis caused by small cell lung cancer (SCLC) is rare. A patient was investigated for primary cancer because of suspected brain metastasis on computed tomography (CT). Baseline F-fluorodeoxyglucose (FDG) positron emission tomography (PET)-CT was positive in the lung and multiple endocrine glands (right thyroid, right breast, pancreatic body, right adrenal gland, and left ovary). Histopathology confirmed small cell lung cancer. The patient's symptoms were alleviated after chemotherapy and brain radiotherapy. Follow-up PET-CT revealed that some of the lesions had disappeared and some had reduced in size. This rare case of multiple endocrine gland metastases from SCLC suggests that whole body PET-CT is a useful tool to detect rare/asymptomatic metastases.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754314 | PMC |
http://dx.doi.org/10.1111/1759-7714.12523 | DOI Listing |
Front Cardiovasc Med
August 2025
Department of Ultrasound, The Affiliated Hospital of Inner Mongolia Medical University, Huhhot, China.
Objective: We identified a novel mutation in the protein kinase cAMP-dependent type I regulatory subunit α () gene in a Chinese patient presenting with multiple recurrent cardiac myxomas, confirming a diagnosis of Carney complex (CNC). By reviewing the relevant literature, we aimed to enhance our understanding of this condition.
Case Presentation: A 12-year-old girl was referred to the Department of Cardiac Surgery at our hospital due to multiple cardiac myxomas.
Front Physiol
August 2025
Department of Rehabilitation Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.
Objective: To explore the exercise capacity in obese patients with severe obstructive sleep apnea syndrome (OSAS) through cardiopulmonary exercise test (CPET).
Methods: In this cross-sectional study, patients with simple obesity (36 cases) and obese patients with severe OSAS (45 cases) admitted to the Department of Rehabilitation Medicine and the Department of General Practice of the Affiliated Wuxi People's Hospital of Nanjing Medical University from September 2019 to January 2024 were collected. Additionally, we included 33 patients (BMI<28 kg/m,AHI<5/hour) as a control group.
Ecotoxicol Environ Saf
September 2025
China CDC Key Laboratory of Environment and Population Health, National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing 100021, China; National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute of Environm
New evidence has revealed ambient fine particulate matter < 2.5 μm (PM) may have endocrine disrupting effect, such as thyroid hormone disorder, while which PM constituents contributed to the effect was debatable. The study aimed to identify the specific PM constituents regarding to acute endocrine disrupting effect.
View Article and Find Full Text PDFJ Clin Endocrinol Metab
September 2025
Endocrinology & Nutrition Department, Hospital Universitario de Vall d´Hebron, Barcelona, Spain.
Objective: Pituitary adenomas (PAs) are one of the three major lesions in Multiple Endocrine Neoplasia type 1 (MEN1), with a prevalence of 32 to 58%, yet their specific risk factors remain unidentified. This study aimed to identify predictors influencing PA occurrence in MEN1.
Methods: This nationwide, multicenter, retrospective cohort study involved 240 MEN1 patients, 55.
Diabetes Ther
September 2025
Department of Diabetes and Endocrinology, Guy's and St Thomas' NHS Trust, London, UK.
Introduction: This post hoc analysis of an A Toujeo Observational Study (ATOS) aims to evaluate the real-world effectiveness and safety of insulin glargine 300 U/ml (Gla-300) in high-risk subgroups of insulin-naïve people with type 2 diabetes (PwT2D) from multiple geographical regions (Asia, the Middle East, North Africa, Latin America, and Eastern Europe).
Methods: In these post hoc analyses of ATOS, a real-world, 12-month, prospective study included 4422 insulin-naïve adults (age ≥ 18 years) with type 2 diabetes (T2D) uncontrolled (HbA > 7% and ≤ 11%) on one or more oral antidiabetic drugs (OADs) who initiated Gla-300 treatment as per routine practice. Primary and secondary endpoints were studied according to renal impairment (RI) status (without or with) and age group (≥ 70 years).